CADENCE PHARMACEUTICALS, INC COM STK
CADX
CADX was delisted on the 18th of March, 2014.
100 hedge funds and large institutions have $457M invested in CADENCE PHARMACEUTICALS, INC COM STK in 2013 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 30 increasing their positions, 30 reducing their positions, and 15 closing their positions.
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
51% more capital invested
Capital invested by funds: $304M → $457M (+$154M)
11% more funds holding
Funds holding: 90 → 100 (+10)
6% more call options, than puts
Call options by funds: $2.93M | Put options by funds: $2.77M
0% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$18.8M |
| 2 |
VAM
Visium Asset Management
New York
|
+$15.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$6.37M |
| 4 |
Millennium Management
New York
|
+$5.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$34M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.95M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.89M |
| 4 |
CII
CR Intrinsic Investors
Stamford,
Connecticut
|
-$4.83M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$959K |
CADX Hedge Fund Activity: Q4 2013 in Review
100 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in CADENCE PHARMACEUTICALS, INC COM STK (CADX) for Q4 2013, worth a combined $457M — up 51% from $304M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CADX positions and 15 closed out — a net gain of 10 holders — while 30 added to existing stakes and 30 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $18.8M. The largest seller was Fidelity Investments, cutting an estimated $34M.
- 100 institutional investors held CADENCE PHARMACEUTICALS, INC COM STK (CADX) as of Q4 2013, up from 90 in Q3 2013.
- Funds reported $457M of CADENCE PHARMACEUTICALS, INC COM STK stock for Q4 2013, up 51% quarter-over-quarter.
- 25 funds opened new CADENCE PHARMACEUTICALS, INC COM STK positions in Q4 2013 and 15 closed out, a net change of +10 holders.
- The largest CADENCE PHARMACEUTICALS, INC COM STK buyer in Q4 2013 was Consonance Capital Management, an estimated $18.8M added.
- The largest CADENCE PHARMACEUTICALS, INC COM STK seller in Q4 2013 was Fidelity Investments, an estimated $34M sold.
Based on aggregated 13F filings for Q4 2013.